Clinical Trial Update: Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating LMP-, BARF1-, and EBNA1-specific cytotoxic T cells for EBV-positive lymphomas; Hodgkin and Non-Hodgkin lymphoma included; results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Active Ebv Infection
• Hodgkin Lymphoma
• Nasopharyngeal Carcinoma
• Nk-cell Lymphoproliferative Disease
• Non-hodgkin Lymphoma
• Smooth Muscle Tumor

Drugs mentioned

• LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes

Snippet

Sponsor: Baylor College of Medicine | Conditions: Hodgkin Disease, Non-Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-02-24